Open AccessOverexpression of human cyclin D1 reduces the transforming growth factor beta (TGF-beta) type II receptor and growth inhibition by TGF-beta 1 in an immortalized human esophageal epithelial cell line.
Author(s) -
Aikou Okamoto,
Wei Jiang,
SeongJin Kim,
Elisa A. Spillare,
G. D. Stoner,
I. Bernard Weinstein,
C. C. Harris
Publication year - 1994
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.91.24.11576
Subject(s) - cyclin d1 , cancer research , biology , cyclin d , transforming growth factor beta , transforming growth factor, beta 3 , cyclin , transfection , cell growth , cyclin a2 , cell cycle , carcinogenesis , transforming growth factor , cell culture , microbiology and biotechnology , cyclin b , tgf alpha , cell , gene , genetics , epidermal growth factor
Cyclin D1 has been implicated in G1 cell cycle progression and is frequently amplified, overtranscribed, and oversynthesized in human tumors, including esophageal carcinomas. To further address the role of cyclin D1 in cell cycle control and tumorigenesis, we have stably transfected the human cyclin D1 in the nontumorigenic esophageal epithelial cell line HET-1A. These transfected cells, which express increased amounts of cyclin D1, have enhanced colony-forming efficiency and saturation density and are resistant to growth inhibition by TGF-beta 1 compared with the parental cell line or a control vector cell clone. The clones which express increased amounts of cyclin D1 exhibited a decrease in the amount of TGF-beta type II receptor, indicating a plausible mechanism for their diminished response to TGF-beta 1. Therefore, deregulated expression of the cyclin D1 gene can modulate the negative growth factor pathway of TGF-beta 1 and may disturb the control of epithelial cell proliferation in esophageal carcinogenesis.